TICKERNERD
Menu
ERNAERNAHealthcare · Biotechnology

ERNA Stock Forecast: Ernexa Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$2.49
+4.18% on the day

The 1 Wall Street analysts covering Ernexa Therapeutics, Inc. hold a median 12-month price target of $30 — +1104.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.9M
Ticker Nerd rank
37 / 100
Median analyst target
$30
Analysts covering
1
Revenue$0.0
Operating income−$4.1M
Net income−$4.0M
Free cash flow−$4.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.9%
1M
−40.6%
YTD
−91.7%
1Y
−92.7%
From 52W high
−94.7%
From 52W low
+11.2%
$2
$47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ERNA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ernexa Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
96
Accruals
91
Revisions
53
Growth
52
Issuance
44
Momentum
26
Quality
16
Volatility
14
Value
8

Size (96): Smaller than most of the companies we track.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ERNA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ERNA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26ERNAHigh $30Median $30Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $30Median $30High $30

The green dot is the last close — the median target sits +1104.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 May 2026Brookline CapitalInitiatesBuy$30
14 Dec 2022Morgan StanleyMaintainsEqual-Weight—
12 Dec 2022B of A SecuritiesUpgradeBuy—
14 Nov 2022NeedhamMaintainsBuy—
10 Aug 2022NeedhamMaintainsBuy—
15 July 2022Morgan StanleyMaintainsEqual-Weight—
12 May 2022JP MorganUpgradeOverweight—
11 May 2022NeedhamMaintainsBuy—
2 Mar 2022NeedhamMaintainsBuy—
11 Nov 2021NeedhamMaintainsBuy—
1 Oct 2021NeedhamMaintainsBuy—
16 June 2021Morgan StanleyMaintainsEqual-Weight—
13 May 2021NeedhamMaintainsBuy—
21 Apr 2021JP MorganInitiatesNeutral—
19 Apr 2021NeedhamMaintainsBuy—
26 Mar 2021Morgan StanleyInitiatesEqual-Weight—
25 Mar 2021NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ERNA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ERNA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Ernexa Therapeutics, Inc. returned −92.7% against +16.2% for the S&P 500, dividends included.

ERNA vs S&P 500, last 12 monthsTotal return, rebased to 100
050100Jan 26Apr 26Jul 26Oct 26ERNAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ERNA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Ernexa Therapeutics, Inc. (ERNA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
—
Price / book
0.8×

Cheaper than 77% of US stocks

EV / EBITDA
0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−320.7%

Higher than 5% of US stocks

Return on assets
−105.6%

Higher than 2% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ernexa Therapeutics, Inc. (ERNA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ernexa Therapeutics, Inc. has a market value of $3.9M and an enterprise value of −$1.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$12.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$8.9M.

  • Shares outstanding: 1.2M.

  • Trailing P/E: 0.0×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Ernexa Therapeutics, Inc. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

ERNA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ERNAErnexa Therapeutics, Inc.$3.9M
37
PMCBPharmaCyte Biotech, Inc.$4.3M
29
DRMADermata Therapeutics, Inc.$4.3M
28
CLDICalidi Biotherapeutics, Inc.$3.8M
23
PCSAProcessa Pharmaceuticals, Inc.$3.8M
20
EOCNEocene Ltd.$3.8M
28
GRIGRI Bio, Inc.$3.7M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ernexa Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ERNA news & analysis

Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center

GlobeNewsWire · 6 Oct 2026positive

Ernexa Therapeutics said preclinical data on ERNA-101 was selected for a flash talk at Nature Conferences' Next-Generation Cancer Therapeutics meeting, co-hosted by MD Anderson Cancer Center. The presentation is scheduled for October 6, 2026, in Houston, and will address the candidate's potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade.

Why it matters — The presentation spotlights preclinical research on ERNA-101 and its potential role in ovarian cancer treatment.

Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic

GlobeNewsWire · 1 Oct 2026positive

Ernexa Therapeutics highlighted the appointment of Dr. Robert J. Spiegel to its leadership as the company sharpens its oncology focus and advances ERNA-101 toward the clinic. The CEO discussed how the addition of the accomplished oncology drug developer strengthens Ernexa ahead of clinical development, following ERNA-101 data showing complete tumor clearance and 100% survival in combination with anti-PD-1.

Why it matters — ERNA watchers would care because the appointment of a seasoned oncology drug developer bolsters the company's leadership as it prepares to move its promising ERNA-101 candidate into clinical development.

Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND

GlobeNewsWire · 30 Sept 2026positive

Ernexa Therapeutics reported compelling ERNA-101 safety results across three IND-enabling studies, including a repeat-dose GLP toxicology study showing no drug-related adverse findings at any dose level and a single-dose assessment with no evidence of acute cytokine release. The company is advancing toward a planned Q4 2026 IND filing.

Why it matters — A clean safety profile across these pivotal IND-enabling studies removes a key development hurdle and strengthens the path toward Ernexa's planned regulatory filing for ERNA-101.

Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy

GlobeNewsWire · 29 Sept 2026positive

Ernexa Therapeutics has been selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa, which recognizes the company among emerging innovators in the cell and gene therapy sector. The selection highlights its ERNA-101 program and focused oncology strategy.

Why it matters — Selection for the Emerging Track provides Ernexa with increased visibility within the cell and gene therapy investment community, reinforcing recognition of its ERNA-101 program and oncology focus.

Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D.

GlobeNewsWire · 17 Sept 2026positive

Ernexa Therapeutics announced the appointment of Robert J. Spiegel, M.D., an accomplished biopharmaceutical executive, to its leadership. Dr. Spiegel brings decades of global clinical development, regulatory, and oncology experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics.

Why it matters — The addition of a veteran drug-development and regulatory leader could strengthen Ernexa's clinical and regulatory capabilities.

FAQ

Frequently asked questions about ERNA stock

What is the ERNA stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Ernexa Therapeutics, Inc. have a median 12-month price target of $30, with estimates ranging from $30 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ERNA stock a buy right now?

Of the 1 analysts covering Ernexa Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ernexa Therapeutics, Inc. 37 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ERNA?

As at 8 Oct 2026, Ernexa Therapeutics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

Will ERNA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1104.8% from the last close, and Ticker Nerd's factor model ranks Ernexa Therapeutics, Inc. 37 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ERNA stock forecast for 2030?

No analyst covering Ernexa Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ERNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $30 over the next 12 months.

How has ERNA stock performed over the past year?

Ernexa Therapeutics, Inc. returned -92.7% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ernexa Therapeutics, Inc. do?

Ernexa Therapeutics Inc. is a biotechnology company focused on developing cell-based therapies for advanced cancer and autoimmune diseases.

What is the latest news on ERNA?

The most recent item we track (GlobeNewsWire, 6 Oct 2026): "Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center". Ernexa Therapeutics said preclinical data on ERNA-101 was selected for a flash talk at Nature Conferences' Next-Generation Cancer Therapeutics meeting, co-hosted by MD Anderson Cancer Center. The presentation is scheduled for October 6, 2026, in Houston, and will address the candidate's potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade.

Company

About Ernexa Therapeutics, Inc.

Ernexa Therapeutics Inc. is a biotechnology company focused on developing cell-based therapies for advanced cancer and autoimmune diseases. The company’s current programs center on engineered induced pluripotent stem cells and induced mesenchymal stem cells designed to create off-the-shelf, allogeneic treatments that can be manufactured without patient-specific cell harvesting. Its pipeline includes preclinical product candidates aimed at ovarian cancer and rheumatoid arthritis, reflecting its emphasis on therapeutic areas with high unmet medical need. Ernexa Therapeutics Inc. works at the intersection of cell engineering, immunology, and regenerative medicine, using proprietary mRNA and gene-modification technologies to direct how cells behave and deliver targeted biological effects. Headquartered in Cambridge, Massachusetts, the company operates as a clinical-stage biotechnology developer with a focused role in the evolving market for next-generation cellular medicines.

CEO Mr. Sanjeev Luther · 5 employees · United States · https://www.ernexatx.com